JP2021508317A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508317A5
JP2021508317A5 JP2020529479A JP2020529479A JP2021508317A5 JP 2021508317 A5 JP2021508317 A5 JP 2021508317A5 JP 2020529479 A JP2020529479 A JP 2020529479A JP 2020529479 A JP2020529479 A JP 2020529479A JP 2021508317 A5 JP2021508317 A5 JP 2021508317A5
Authority
JP
Japan
Prior art keywords
hours
dose
administered
steroid
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020529479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/063502 external-priority patent/WO2019109053A1/en
Publication of JP2021508317A publication Critical patent/JP2021508317A/ja
Publication of JP2021508317A5 publication Critical patent/JP2021508317A5/ja
Pending legal-status Critical Current

Links

JP2020529479A 2017-12-01 2018-11-30 遺伝子操作された細胞の投与および調節のための方法 Pending JP2021508317A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762593878P 2017-12-01 2017-12-01
US62/593,878 2017-12-01
US201762596773P 2017-12-08 2017-12-08
US62/596,773 2017-12-08
US201862633599P 2018-02-21 2018-02-21
US62/633,599 2018-02-21
US201862679764P 2018-06-01 2018-06-01
US201862679763P 2018-06-01 2018-06-01
US62/679,763 2018-06-01
US62/679,764 2018-06-01
PCT/US2018/063502 WO2019109053A1 (en) 2017-12-01 2018-11-30 Methods for dosing and for modulation of genetically engineered cells

Publications (2)

Publication Number Publication Date
JP2021508317A JP2021508317A (ja) 2021-03-04
JP2021508317A5 true JP2021508317A5 (enExample) 2022-01-06

Family

ID=64734219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529479A Pending JP2021508317A (ja) 2017-12-01 2018-11-30 遺伝子操作された細胞の投与および調節のための方法

Country Status (7)

Country Link
US (1) US20210198372A1 (enExample)
EP (1) EP3716980A1 (enExample)
JP (1) JP2021508317A (enExample)
KR (1) KR20200116081A (enExample)
CN (1) CN111989106A (enExample)
MA (1) MA51210A (enExample)
WO (1) WO2019109053A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
DK3294906T3 (en) 2015-05-11 2024-08-05 Natera Inc Methods for determining ploidy
DK3443119T3 (da) 2016-04-15 2022-05-23 Natera Inc Fremgangsmåde til bestemmelse af lunge cancer
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
CA3053539A1 (en) * 2017-02-27 2018-08-30 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
JP2020524519A (ja) 2017-06-20 2020-08-20 ザ メディカル カレッジ オブ ウィスコンシン,インコーポレイテッドThe Medical College of Wisconsin, Inc. 全セルフリーdnaによる移植合併症リスクの評価
MA50855A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Procédé de génération de compositions thérapeutiques de cellules modifiées
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
BR112021010354A2 (pt) * 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) * 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CA3217687A1 (en) * 2021-05-11 2022-11-17 Muhammad S. AKRAM Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy
US20230197278A1 (en) * 2021-07-13 2023-06-22 Genentech, Inc. Multi-variate model for predicting cytokine release syndrome

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5298508A (en) 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
AU6781194A (en) 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
WO1997027177A2 (en) 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖t細胞レセプタータンパク質
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
PT1196186E (pt) 1999-07-12 2008-02-14 Genentech Inc Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003050241A2 (en) 2001-12-12 2003-06-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変t細胞レセプターを発現する細胞
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
AU2008257436A1 (en) 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
US20080306134A1 (en) 2007-06-08 2008-12-11 Charlesson, Llc Thalidomide analogs for treating vascular abnormalities
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TGF-β 길항제 다중-표적 결합 단백질
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
AU2012236068A1 (en) 2011-04-01 2013-10-17 Eureka Therapeutics, Inc. T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
EP2697367B1 (en) 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP2804625A4 (en) 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
EP2861622A4 (en) 2012-06-15 2016-06-01 Sinomab Bioscience Ltd Anti-idiotypic anti-CD22 antibodies and uses thereof
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗-cd19嵌合抗原受體治療癌症
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CA2932120C (en) 2013-12-06 2023-09-19 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
MX389823B (es) 2014-10-27 2025-03-20 Fred Hutchinson Cancer Center Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
CN113968912B (zh) 2014-12-05 2025-05-16 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
EP3872094A3 (en) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
KR102602417B1 (ko) 2014-12-05 2023-11-16 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
AU2016263464B2 (en) * 2015-05-20 2021-12-23 Amgen Research (Munich) Gmbh B-cell depletion as a diagnostic marker
CN116334205A (zh) * 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
MA43377A (fr) * 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
RU2018136877A (ru) * 2016-03-22 2020-04-22 СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) Способы раннего вмешательства для профилактики или улучшения состояния токсичности
US20200078400A1 (en) * 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
CN111225675B (zh) * 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
AU2018275891B2 (en) * 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy

Similar Documents

Publication Publication Date Title
JP7034125B2 (ja) Carの抗腫瘍活性のための毒性管理
EP3609914B1 (en) Chimeric antigen receptor t cells targeting the tumor microenvironment
JP2020522489A5 (enExample)
JP2021505615A5 (enExample)
RU2019120398A (ru) Способы определения дозировки cart-клеток
TWI872051B (zh) T細胞受體及其使用方法
IL305621A (en) Methods for training patients for T-cell therapy
KR20230156808A (ko) Car-t 세포의 조절 방법
US20190298771A1 (en) Methods of adoptive cell therapy
JP2019532997A5 (enExample)
JP2022537700A5 (enExample)
JP2024016200A (ja) キメラ抗原受容体療法のt細胞の増殖動態及びその使用
TW202100548A (zh) T細胞受體及其使用方法
TW202100547A (zh) T細胞受體及其使用方法
TWI877145B (zh) T細胞受體及其使用方法
JP2026071229A (ja) 免疫療法由来の有害事象の予測
JP2020522695A5 (enExample)
US20260042827A1 (en) Anti-wt1 antigen-binding proteins and uses thereof
JP2026510915A (ja) 免疫療法の有効性に対する腫瘍微小環境の影響
HK40115899A (zh) 施用嵌合抗原受体免疫疗法的方法
HK40115916A (zh) 施用嵌合抗原受体免疫疗法的方法
WO2025047920A1 (ja) Hla/がん抗原pvt1由来ペプチド複合体特異的抗体
RU2019144333A (ru) Изделия и способы для лечения с использованием адоптивной клеточной терапии
HK40039113A (en) Toxicity management for anti-tumor activity of cars
HK1253365B (en) Toxicity management for anti-tumor activity of cars